G1 Therapeutics (GTHX) Short Interest Ratio & Short Volume → This Wall Street stock prediction just went viral (From Chaikin Analytics) (Ad) Free GTHX Stock Alerts $4.69 +0.04 (+0.86%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics Short Interest DataCurrent Short Volume2,830,000 sharesPrevious Short Volume2,420,000 sharesChange Vs. Previous Month+16.94%Dollar Volume Sold Short$10.67 millionShort Interest Ratio / Days to Cover2.5Last Record DateApril 30, 2024Outstanding Shares52,280,000 sharesPercentage of Shares Shorted5.41%Today's Trading Volume482,113 sharesAverage Trading Volume1,564,921 sharesToday's Volume Vs. Average31% Short Selling G1 Therapeutics ? Sign up to receive the latest short interest report for G1 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGTHX Short Interest Over TimeGTHX Days to Cover Over TimeGTHX Percentage of Float Shorted Over Time Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic G1 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,830,000 shares $10.67 million +16.9%N/A2.5 $3.77 4/15/20242,420,000 shares $10.43 million -12.3%N/A1.9 $4.31 3/31/20242,760,000 shares $11.92 million +2.6%N/A1.9 $4.32 3/15/20242,690,000 shares $8.37 million -7.6%N/A1.9 $3.11 2/29/20242,910,000 shares $9.66 million -12.6%N/A1.5 $3.32 2/15/20243,330,000 shares $7.99 million +27.6%N/A1.8 $2.40 Get the Latest News and Ratings for GTHX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20242,610,000 shares $10.31 million -19.7%N/A1.8 $3.95 1/15/20243,250,000 shares $10.40 million +16.9%N/A2.4 $3.20 12/31/20232,780,000 shares $8.48 million +5.3%N/A2.2 $3.05 12/15/20232,640,000 shares $7.68 million +9.1%N/A2.3 $2.91 11/30/20232,420,000 shares $4.55 million -2.8%N/A3.1 $1.88 11/15/20232,490,000 shares $4.06 million +2.1%N/A4.8 $1.63 10/31/20232,440,000 shares $4.03 million -6.5%N/A4.4 $1.65 10/15/20232,610,000 shares $2.98 million -5.8%N/A3.4 $1.14 9/30/20232,770,000 shares $3.99 million -4.5%N/A3.4 $1.44 9/15/20232,900,000 shares $4.47 million -1.0%N/A3.5 $1.54 8/31/20232,930,000 shares $4.89 million No ChangeN/A3.3 $1.67 8/15/20232,930,000 shares $5.48 million -10.1%N/A3 $1.87 7/31/20233,260,000 shares $7.82 million +4.5%N/A3.2 $2.40 7/15/20233,120,000 shares $7.52 million +1.0%N/A3.6 $2.41 6/30/20233,090,000 shares $7.69 million +20.2%N/A3.9 $2.49 6/15/20232,570,000 shares $7.27 million -13.2%N/A3.1 $2.83 5/31/20232,960,000 shares $7.52 million -5.1%N/A3.3 $2.54 5/15/20233,120,000 shares $9.11 million -5.7%N/A3.3 $2.92 4/30/20233,310,000 shares $9.50 million -12.4%N/A2.8 $2.87 4/15/20233,780,000 shares $10.02 million -10.2%N/A3.2 $2.65 3/31/20234,210,000 shares $11.28 million +14.7%N/A3.4 $2.68 3/15/20233,670,000 shares $12.00 million +28.3%N/A2.9 $3.27 2/28/20232,860,000 shares $10.35 million -6.2%N/A2.2 $3.62 2/15/20233,050,000 shares $11.19 million -2.2%N/A2.3 $3.67 1/31/20233,120,000 shares $24.90 million +1.0%N/A2.7 $7.98 1/15/20233,090,000 shares $19.53 million +20.2%N/A2.7 $6.32 12/30/20222,570,000 shares $13.96 million -46.1%N/A2.3 $5.43 12/15/20224,770,000 shares $29.67 million +5.8%N/A4.3 $6.22 11/30/20224,510,000 shares $26.88 million -26.8%10.9%4 $5.96 11/15/20226,160,000 shares $55.01 million -18.2%14.9%6 $8.93 10/31/20227,530,000 shares $80.27 million +7.0%21.5%8.5 $10.66 10/15/20227,040,000 shares $78.21 million +9.7%20.2%7.3 $11.11 9/30/20226,420,000 shares $80.19 million +65.9%18.4%6.2 $12.49 9/15/20223,870,000 shares $59.79 million +11.9%11.1%3.5 $15.45A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. GTHX Short Interest - Frequently Asked Questions What is G1 Therapeutics' current short interest? Short interest is the volume of G1 Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,830,000 shares of GTHX short. Learn More on G1 Therapeutics' current short interest. What is a good short interest ratio for G1 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GTHX shares currently have a short interest ratio of 2.0. Learn More on G1 Therapeutics's short interest ratio. Which institutional investors are shorting G1 Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of G1 Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is G1 Therapeutics' short interest increasing or decreasing? G1 Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,830,000 shares, an increase of 16.9% from the previous total of 2,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does G1 Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to G1 Therapeutics: 2seventy bio, Inc. (14.59%), Omeros Co. (24.41%), Foghorn Therapeutics Inc. (7.05%), Pyxis Oncology, Inc. (3.95%), Aldeyra Therapeutics, Inc (4.03%), uniQure (6.72%), Puma Biotechnology, Inc. (8.96%), Generation Bio Co. (3.61%), Design Therapeutics, Inc. (9.06%), Ovid Therapeutics Inc. (4.81%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short G1 Therapeutics stock? Short selling GTHX is an investing strategy that aims to generate trading profit from G1 Therapeutics as its price is falling. GTHX shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against G1 Therapeutics? A short squeeze for G1 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GTHX, which in turn drives the price of the stock up even further. How often is G1 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTHX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: 2seventy bio Short Squeeze Omeros Short Squeeze Foghorn Therapeutics Short Squeeze Pyxis Oncology Short Squeeze Aldeyra Therapeutics Short Squeeze uniQure Short Squeeze Puma Biotechnology Short Squeeze Generation Bio Short Squeeze Design Therapeutics Short Squeeze Ovid Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTHX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media